As of 2026-10-15, the Relative Valuation of GT Biopharma Inc (GTBP) is (371.19) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.50 USD, the upside of GT Biopharma Inc based on Relative Valuation is -5810.6%.
The range of the Relative Valuation is (351.80) - (371.58) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 26.5x - 28.2x | 28.0x |
| Forward P/E multiples | 26.7x - 28.5x | 28.3x |
| Fair Price | (351.80) - (371.58) | (371.19) |
| Upside | -5512.3% - -5816.6% | -5810.6% |
| Date | P/E |
| 2026-10-09 | -0.51 |
| 2026-10-08 | -0.45 |
| 2026-10-07 | -0.47 |
| 2026-10-06 | -0.48 |
| 2026-10-05 | -0.47 |
| 2026-10-02 | -0.46 |
| 2026-10-01 | -0.47 |
| 2026-09-30 | -0.49 |
| 2026-09-29 | -0.52 |
| 2026-09-28 | -0.52 |
| 2026-09-25 | -0.52 |
| 2026-09-24 | -0.52 |
| 2026-09-23 | -0.54 |
| 2026-09-22 | -0.54 |
| 2026-09-21 | -0.54 |
| 2026-09-18 | -0.54 |
| 2026-09-17 | -0.57 |
| 2026-09-16 | -0.59 |
| 2026-09-15 | -0.68 |
| 2026-09-14 | -0.88 |
| 2026-09-11 | -0.65 |
| 2026-09-10 | -0.47 |
| 2026-09-09 | -0.45 |
| 2026-09-08 | -0.40 |
| 2026-09-04 | -0.46 |
| 2026-09-03 | -0.48 |
| 2026-09-02 | -0.54 |
| 2026-09-01 | -0.55 |
| 2026-08-31 | -0.54 |
| 2026-08-28 | -0.57 |
| 2026-08-27 | -0.57 |
| 2026-08-26 | -0.55 |
| 2026-08-25 | -0.57 |
| 2026-08-24 | -0.58 |
| 2026-08-21 | -0.55 |
| 2026-08-20 | -0.53 |
| 2026-08-19 | -0.54 |
| 2026-08-18 | -0.52 |
| 2026-08-17 | -0.54 |
| 2026-08-14 | -0.56 |
| 2026-08-13 | -0.56 |
| 2026-08-12 | -0.57 |
| 2026-08-11 | -0.59 |
| 2026-08-10 | -0.61 |
| 2026-08-07 | -0.61 |
| 2026-08-06 | -0.57 |
| 2026-08-05 | -0.60 |
| 2026-08-04 | -0.62 |
| 2026-08-03 | -0.58 |
| 2026-07-31 | -0.56 |